Efficacy and Safety of Double Autologous Hematopoietic Stem Cell Transplantation With Sequential Use of Total Marrow Irradiation and High-dose Melphalan in Multiple Myeloma
AutoHSCT is a standard treatment of patients with MM. According to soem clinical evidence
double autoHSCT provides survival advantage compared to a single procedure. Most frequently
used conditioning regimen consists pf high doses of melphalan (HD-MEL). In some studies it
was used in combination with total body irradiation (TBI), which, however was associated
with significant toxicity. In our center the standard procedure includes TBI as a single
treatment at 1st autoHSCT and HD-Mel at 2nd autoHSCT.
As in MM malignant plasma cells are localized almost exclusively in bone marrow there is
rationale to limit irradiation to bones. For this purpose in the current study we substitute
TBI with TMI. Additional boosts are provided for active sites of disease based on PET/CT
imaging. Our intention is to minimize toxicity while maintaining the treatment efficacy.
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Sebastian Giebel, MD
Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products